Relationship between hepatocellular carcinoma and hepatitis B virus genotype with spontaneous YMDD mutations

World Journal of Gastroenterology

Volumn 19, Issue 24, 2013, Pages 3861-3865

  Yang, Jia Hong ^a   Zhang, Hao ^a   Chen, Xue Bing ^a   Chen, Gao ^a   Wang, Xiu ^a  

^a PEOPLE S HOSPITAL OF DEYANG CITY   (China)

Author keywords

Hepatitis B virus; Hepatitis B virus genotype; Liver cirrhosis; Primary hepatocellular carcinoma; YMDD mutation

Indexed keywords

HEPATITIS B (E) ANTIGEN; UNCLASSIFIED DRUG; VIRUS DNA;

ADULT; AGED; ARTICLE; DISEASE ASSOCIATION; DNA DENATURATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENOTYPE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; REAL TIME POLYMERASE CHAIN REACTION; RISK FACTOR; SPONTANEOUS MUTATION; VIRUS LOAD; VIRUS STRAIN;

EID: 84879561325     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v19.i24.3861     Document Type: Article

References (27)

1. Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat 2004; 11: 97-107 [PMID: 14996343 DOI: 10.1046/j.1365-2893.2003.00487.x]
2. Alter MJ. Epidemiology of hepatitis B in Europe and worldwide. J Hepatol 2003; 39 Suppl 1: S64-S69 [PMID: 14708680 DOI: 10.1016/S0168-8278(03)00141-7]
3. Custer B, Sullivan SD, Hazlet TK, Iloeje U, Veenstra DL, Kowdley KV. Global epidemiology of hepatitis B virus. J Clin Gastroenterol 2004; 38: S158-S168 [PMID: 15602165 DOI: 10.1097/00004836-200411003-00008]
4. Lu FM, Zhuang H. Management of hepatitis B in China. Zhonghua Yixve Zazhi 2009; 122: 3-4 [PMID: 19187608 DOI: 10.3760/cma.j.issn.0366-6999.2009.01.001]
5. Liang X, Bi S, Yang W, Wang L, Cui G, Cui F, Zhang Y, Liu J, Gong X, Chen Y, Wang F, Zheng H, Wang F, Guo J, Jia Z, Ma J, Wang H, Luo H, Li L, Jin S, Hadler SC, Wang Y. Epi-demiological serosurvey of hepatitis B in China--declining HBV prevalence due to hepatitis B vaccination. Vaccine 2009; 27: 6550-6557 [PMID: 19729084 DOI: 10.1016/j.vaccine. 2009.08.048]
6. Liang X, Bi S, Yang W, Wang L, Cui G, Cui F, Zhang Y, Liu J, Gong X, Chen Y, Wang F, Zheng H, Wang F, Guo J, Jia Z, Ma J, Wang H, Luo H, Li L, Jin S, Hadler SC, Wang Y. Evaluation of the impact of hepatitis B vaccination among children born during 1992-2005 in China. J Infect Dis 2009; 200: 39-47 [PMID: 19469708 DOI: 10.1086/599332]
7. Tan Y. Hepatitis B virus infection and the risk of hepatocel-lular carcinoma. World J Gastroenterol 2011; 17: 4853-4857 [DOI: 10.3748/wjg.v17.i44.4853]
8. But DY, Lai CL, Yuen MF. Natural history of hepatitis-related hepatocellular carcinoma. World J Gastroenterol 2008; 14: 1652-1656 [PMID: 18350595 DOI: 10.3748/wjg.14.1652]
9. Lee WM. Hepatitis B virus infection. N Engl J Med 1997; 337: 1733-1745 [PMID: 9392700 DOI: 10.1056/NEJM1997121 13372406]
10. Liu C, Wang YM, Fan K. Epidemiological and clinical features of hepatitis B virus related liver failure in China. World J Gastroenterol 2011; 17: 3054-3059 [PMID: 21799653 DOI: 10.3748/wjg.v17.i25.3054]
11. Liaw YF. Prevention and surveillance of hepatitis B virus-related hepatocellular carcinoma. Semin Liver Dis 2005; 25 Suppl 1: 40-47 [PMID: 16103980 DOI: 10.1053/j.gastro.2004.09.045]
12. Moskovitz DN, Osiowy C, Giles E, Tomlinson G, Heathcote EJ. Response to long-term lamivudine treatment (up to 5 years) in patients with severe chronic hepatitis B, role of genotype and drug resistance. J Viral Hepat 2005; 12: 398-404 [PMID: 15985011 DOI: 10.1111/j.1365-2893.2005.00613.x]
13. Lai CL, Dienstag J, Schiff E, Leung NW, Atkins M, Hunt C, Brown N, Woessner M, Boehme R, Condreay L. Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. Clin Infect Dis 2003; 36: 687-696 [PMID: 12627352 DOI: 10.1086/368083]
14. Yildiz O, Aygen B, Demirtürk N, Demirdal T, Inan D, Yildirmak T, Kantürk A, Tütüncü E. Lamivudine resistance mutations in patients infected with hepatitis B virus genotype D. World J Gastroenterol 2011; 17: 4987-4992 [PMID: 22174548 DOI: 10.3748/wjg.v17.i45.4987]
15. Liaw YF, Chien RN, Yeh CT, Tsai SL, Chu CM. Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy. Hepatology 1999; 30: 567-572 [PMID: 10421670 DOI: 10.1002/hep.510300221]
16. Liaw YF, Chien RN, Yeh CT. No benefit to continue lamivudine therapy after emergence of YMDD mutations. Antivir Ther 2004; 9: 257-262 [PMID: 15134188]
17. Matsuda M, Suzuki F, Suzuki Y, Tsubota A, Akuta N, Ho-saka T, Someya T, Kobayashi M, Saitoh S, Arase Y, Satoh J, Takagi K, Kobayashi M, Ikeda K, Kumada H. Low rate of YMDD motif mutations in polymerase gene of hepatitis B virus in chronically infected patients not treated with lamivudine. J Gastroenterol 2004; 39: 34-40 [PMID: 14767732 DOI: 10.1007/s00535-003-1242-4]
18. Li D, Gu HX, Zhang SY, Zhong ZH, Zhuang M, Hattori T. YMDD mutations and genotypes of hepatitis B virus in northern China. Jpn J Infect Dis 2006; 59: 42-45 [PMID: 16495633]
19. Yang HI, Yeh SH, Chen PJ, Iloeje UH, Jen CL, Su J, Wang LY, Lu SN, You SL, Chen DS, Liaw YF, Chen CJ. Associations between hepatitis B virus genotype and mutants and the risk of hepatocellular carcinoma. J Natl Cancer Inst 2008; 100: 1134-1143 [PMID: 18695135 DOI: 10.1093/jnci/djn243]
20. Ou Z, Zhang Y, Zhang R, He Y, He X. Relationship between Mutation of HBV YMDD Motif and Pathogenesis of Hepatocellular Carcinoma. Redai Yixve Zazhi 2008; 6: 525-528 [DOI: 10.3969/j.issn.1672-3619.2008.06.002]
21. Hosaka T, Suzuki F, Kobayashi M, Hirakawa M, Kawamura Y, Yastuji H, Sezaki H, Akuta N, Suzuki Y, Saitoh S, Arase Y, Ikeda K, Miyakawa Y, Kumada H. Development of HCC in patients receiving adefovir dipivoxil for lamivudine-resistant hepatitis B virus mutants. Hepatol Res 2010; 40: 145-152 [PMID: 19788684 DOI: 10.1111/j.1872-034X.2009.00582.xHEP582]
22. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology 2005; 42: 1208-1236 [PMID: 16250051 DOI: 10.1002/hep.20933]
23. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003; 362: 1907-1917 [PMID: 14667750 DOI: 10.1016/ S0140-6736(03)14964-1]
24. Chan HL, Hui AY, Wong ML, Tse AM, Hung LC, Wong VW, Sung JJ. Genotype C hepatitis B Virus infection is associated with an increased risk of hepatocellular carcinoma. Gut 2004; 53: 1494-1498 [PMID: 15361502 DOI: 10.1136/gut.2003.033324]
25. Shi YH. Correlation between hepatitis B virus genotypes and clinical outcomes. Jpn J Infect Dis 2012; 65: 476-482 [PMID: 23183198 DOI: 10.7883/yoken.65.476]
26. Huang Y, Wang Z, Zeng G, Ma S, Hou J. Study on the relationship between primary hepatocellular carcinoma and HBV genotypes in Guangdong Province of China. Zhonghua Chuanranbing Zazhi 2007; 25: 215-218
27. Kobayashi S, Ide T, Sata M. Detection of YMDD motif mutations in some lamivudine-untreated asymptomatic hepatitis B virus carriers. J Hepatol 2001; 34: 584-586 [PMID: 11394659 DOI: 10.1016/ S0168-8278(00)00023-4]